← Back to Home

One Application for Multiple Therapies: FDA Proposes Review Framework for Personalized Gene Editing

Can gene-editing therapies tailored to different disease-causing mutations in the same disease share a marketing application? A new FDA draft proposes a conditional pathway for grouping them, potentially allowing subsequent variants to draw on existing evidence, while requiring clear limits on inferences about safety and efficacy.

By SURL BioNews

For patients with rare disease-causing mutations, gene-editing tools may need to be adjusted even when the disease name is the same. If every adjustment must undergo a separate development and marketing application process, personalized treatment faces a formidable barrier. New draft guidance from the U.S. Food and Drug Administration (FDA) seeks to allow these therapy variants that share a core design to be included in a single biologics license application (BLA).

A notice announcing the draft’s availability was published in the Federal Register on October 28, 2026. The draft addresses both initial applications and the management of variants added after approval. The FDA explicitly states that the document remains open for comment, is not yet for implementation, and contains recommendations that are not legally binding; the deadline for this round of comments is November 27. This is a proposed review pathway, not a marketing approval for any therapy.

According to reporting by the regulatory professional organization RAPS, FDA official Andrew Byrnes said at a briefing that requiring separate development, clinical studies, and marketing applications for each patient’s therapy would be neither feasible nor necessary. However, the draft sets clear eligibility conditions: the disease must be caused by a known pathogenic variant in a single gene, and therapy variants within the same application must share the same mechanism of action and aim to achieve the same editing outcome.

At the framework’s core is the “individualized feature space” (IFS), which defines in advance which editing components may change and the extent of those changes. For example, guide RNA used to identify a DNA location may have its sequence adjusted for different patient mutations, but must still meet shared design and safety conditions. The FDA encourages developers to plan these boundaries during clinical development and support their rationale with scientific evidence.

If a therapy variant added after approval falls within the established boundaries and meets in vitro safety and activity criteria, the draft treats it as a manufacturing change that can be incorporated through a BLA supplement. When existing clinical evidence is sufficient to support inference, a separate clinical study would generally not be required for each new variant. The key is an understandable and predictable relationship between in vitro results and safety and efficacy in humans.

A shared application must still address the risks of each variant individually. Different guide RNAs may produce different off-target edits, requiring separate assessments of unintended DNA changes and updates to manufacturing information and labeling. If a new variant’s risks cannot be reliably inferred from existing evidence, additional clinical data will be required. Even if mutations are in the same gene, treating a clinically distinct disease constitutes a new indication and requires corresponding clinical evidence.

For mutations found in only a very small number of patients, this approach could allow knowledge accumulated through one development effort to serve as the foundation for subsequent personalized therapies. But how much evidence can be shared depends on whether developers can demonstrate continuity across variants. The draft itself also does not cover the full design of clinical trials needed to support marketing approval. Evidence and manufacturing work remain between establishing an application framework and patients actually receiving treatment.

References

  1. FDA / Federal Register
  2. FDA
  3. FDA
  4. Regulatory Affairs Professionals Society (RAPS)